



VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, MA 02139-4242
Tel. 617.444.6100 Fax 617.444.6680
www.vrtx.c m

FAX**OFFICIAL****RECEIVED
CENTRAL FAX CENTER****AFTER FINAL****DEC 03 2003**

To	TC 1624
	Examiner Deepak Rao
Company	USPTO
FAX	(703) 308-4556
From	Andrea Robidoux
Date	December 2, 2003
Subject	Application No. 10/071,699 Attorney Docket No. VPI/01-103 US
Total Pages	48

Message or Comment**Response to Final Office Action****CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this correspondence, and any documents referred to as attached hereto, is/are being transmitted to the United States Patent and Trademark Office, Facsimile Number: (703)308-4556 on this 2 day of December, 2003.

Andrea L. G. Robidoux

If any problems occur with this fax transmittal, please call (617) 444-6731 immediately.

FAX Number (617) 444-6483 Legal Department**CONFIDENTIALITY NOTICE**

The information and the documents transmitted by this telecopy are privileged and contain confidential information intended only for the person(s) names above. Any other distribution, copying or disclosure is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original to us without making a copy.

OFFICIAL

VPI/01-103 US

**RECEIVED
CENTRAL FAX CENTER**

DEC 03 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Deepak R. Rao
Group Art Unit: 1624
Applicant: Jingrong Cao, et al.
Serial No.: 10/071,699
Filing Date: February 8, 2002
For: HETEROCYCLIC INHIBITORS OF ERK2 AND
USES THEREOF

Cambridge, Massachusetts
December 2, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO FINAL OFFICE ACTION AND AMENDMENT

Dear Examiner Rao:

This is in response to the Office communication dated November 25, 2003 relating to the above-identified application. That Office Action was a final Action. Because this response is submitted within 2 months from the mailing date of said Office Action, Applicants respectfully request issuance of an Advisory Action pursuant to MPEP § 706.07 or Notice of Allowance pursuant to 37 CFR § 1.311, as appropriate.

INTRODUCTORY MATTER

Applicants acknowledge that claims 1-42, 54-60, 63, and 67-70 are allowed whereas claims 48-51 and 65 are rejected.

Please amend the application as follows: